HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Immunogenetic prognosis and long-term results of surgery for gastric cancer].

Abstract
A link between HLA allelic variants and long-term results of surgery for gastric tumors was established on the basis of a 10-years follow-up of 112 cancer patients (stage I-II--37.9, III-IV--62.1%; radical surgery--44.6%). HLA class I was studied in a lymphocytotoxic test; HLA class II--gene DRBI specificity using polymerase chain reaction of peripheral blood cell DNA. The control group included healthy subjects living in the city of Novosibirsk (n = 341). High frequency of antigens HLA-B41, -DR1, -DR7 (p < 0.01) co-occurred with HLA-A2, -B12, -B13 and -B18 presence (p < 0.05) in breast cancer patients. Clinical manifestations of cancer were shown to develop in HLA-A1, -B8, -B15, -DR3 and -DR5 carriers at early stages. Tumor development at later stages (III-IV) was associated with HLA-A2, -B12, -B17, -B35, -B41 and -DR7. A link was registered between lethality rate, on the one hand, and HLA-A3, -B22, and, in particular, DR4, on the other, while remission of more than 7-years--with HLA-A11, -B13, -B21 and -DR5. HLA-B22/DR3 phenotype involved worse prognosis in radically-treated patients whereas that of HLA-B8/DR3--a better one.
AuthorsI Iu Korotkova, D N Egorov, I G Solov'eva, M M Cherenkova, K V Vardosanidze, V V Abramov, V I Konenkov
JournalVoprosy onkologii (Vopr Onkol) Vol. 51 Issue 6 Pg. 672-9 ( 2005) ISSN: 0507-3758 [Print] Russia (Federation)
PMID17037033 (Publication Type: English Abstract, Journal Article)
Chemical References
  • HLA Antigens
Topics
  • Aged
  • Cytotoxicity Tests, Immunologic
  • Female
  • Gene Frequency
  • Genes, MHC Class I
  • Genes, MHC Class II
  • HLA Antigens (genetics)
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Polymerase Chain Reaction
  • Predictive Value of Tests
  • Prognosis
  • Stomach Neoplasms (genetics, immunology, mortality, surgery)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: